2019 Q4 Form 10-Q Financial Statement
#000110820519000020 Filed on November 05, 2019
Income Statement
| Concept | 2019 Q4 | 2019 Q3 | 2018 Q3 |
|---|---|---|---|
| Revenue | $3.287M | $2.856M | $2.847M |
| YoY Change | 19.31% | 0.32% | 16.49% |
| Cost Of Revenue | $160.0K | $150.0K | $150.0K |
| YoY Change | 6.67% | 0.0% | 25.0% |
| Gross Profit | $3.130M | $2.710M | $2.690M |
| YoY Change | 19.92% | 0.74% | 15.95% |
| Gross Profit Margin | 95.22% | 94.89% | 94.49% |
| Selling, General & Admin | $3.000M | $2.890M | $4.130M |
| YoY Change | -1.32% | -30.02% | 21.11% |
| % of Gross Profit | 95.85% | 106.64% | 153.53% |
| Research & Development | $7.460M | $5.147M | $4.983M |
| YoY Change | 58.39% | 3.29% | -62.76% |
| % of Gross Profit | 238.34% | 189.93% | 185.24% |
| Depreciation & Amortization | $30.00K | $30.00K | $40.00K |
| YoY Change | -25.0% | -25.0% | -42.86% |
| % of Gross Profit | 0.96% | 1.11% | 1.49% |
| Operating Expenses | $10.46M | $5.147M | $4.983M |
| YoY Change | 34.97% | 3.29% | -62.76% |
| Operating Profit | -$7.334M | -$5.323M | -$6.417M |
| YoY Change | 42.46% | -17.05% | -55.66% |
| Interest Expense | $100.0K | $0.00 | $972.0K |
| YoY Change | -112.66% | -100.0% | -12.35% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$1.380M | -$1.113M | -$806.0K |
| YoY Change | 38.09% | -18.26% | |
| Pretax Income | -$8.610M | -$6.440M | -$7.220M |
| YoY Change | 44.95% | -10.8% | -53.3% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$8.609M | -$6.436M | -$7.223M |
| YoY Change | 44.91% | -10.9% | -53.27% |
| Net Earnings / Revenue | -261.91% | -225.35% | -253.71% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$259.3K | -$194.0K | -$217.7K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 33.20M shares | 33.20M shares | 33.18M shares |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2019 Q4 | 2019 Q3 | 2018 Q3 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $20.50M | $28.00M | $30.80M |
| YoY Change | -15.64% | -9.09% | -55.49% |
| Cash & Equivalents | $15.43M | $21.40M | $25.56M |
| Short-Term Investments | $5.100M | $6.700M | $5.300M |
| Other Short-Term Assets | $1.300M | $1.800M | $1.100M |
| YoY Change | 62.5% | 63.64% | -21.43% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $3.244M | $2.897M | $2.855M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $25.00M | $32.68M | $34.82M |
| YoY Change | -10.58% | -6.12% | -52.31% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $154.0K | $203.0K | $312.0K |
| YoY Change | -42.32% | -34.94% | -18.75% |
| Goodwill | $9.000M | $8.982M | $8.982M |
| YoY Change | 0.2% | 0.0% | 0.0% |
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $3.000K | $3.000K | $3.000K |
| YoY Change | 50.0% | 0.0% | 0.0% |
| Total Long-Term Assets | $10.10M | $9.561M | $9.450M |
| YoY Change | 7.44% | 1.17% | 0.86% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $25.00M | $32.68M | $34.82M |
| Total Long-Term Assets | $10.10M | $9.561M | $9.450M |
| Total Assets | $35.11M | $42.24M | $44.27M |
| YoY Change | -6.04% | -4.57% | -46.26% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $4.465M | $2.478M | $3.008M |
| YoY Change | 53.49% | -17.62% | -53.86% |
| Accrued Expenses | $1.910M | $1.831M | $3.300M |
| YoY Change | -44.75% | -44.52% | 30.54% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | $0.00 | $6.900M |
| YoY Change | -100.0% | -100.0% | 34.87% |
| Total Short-Term Liabilities | $6.541M | $4.718M | $13.23M |
| YoY Change | -50.63% | -64.35% | -6.57% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $30.20M |
| YoY Change | -100.0% | -100.0% | -20.02% |
| Other Long-Term Liabilities | $0.00 | $0.00 | $29.00K |
| YoY Change | -100.0% | -100.0% | |
| Total Long-Term Liabilities | $0.00 | $0.00 | $30.23M |
| YoY Change | -100.0% | -100.0% | -19.94% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $6.541M | $4.718M | $13.23M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $30.23M |
| Total Liabilities | $69.02M | $68.26M | $43.48M |
| YoY Change | 64.87% | 56.99% | -16.25% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$1.017B | -$1.000B | -$978.9M |
| YoY Change | 3.26% | 2.16% | 3.67% |
| Common Stock | $983.1M | $982.4M | $979.7M |
| YoY Change | 0.28% | 0.27% | 0.36% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | $0.00 | ||
| YoY Change | -100.0% | ||
| Treasury Stock Shares | 0.000 shares | ||
| Shareholders Equity | -$33.91M | -$26.02M | $782.0K |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $35.11M | $42.24M | $44.27M |
| YoY Change | -6.04% | -4.57% | -46.26% |
Cashflow Statement
| Concept | 2019 Q4 | 2019 Q3 | 2018 Q3 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$8.609M | -$6.436M | -$7.223M |
| YoY Change | 44.91% | -10.9% | -53.27% |
| Depreciation, Depletion And Amortization | $30.00K | $30.00K | $40.00K |
| YoY Change | -25.0% | -25.0% | -42.86% |
| Cash From Operating Activities | -$5.600M | -$6.710M | -$8.230M |
| YoY Change | 13.36% | -18.47% | -50.06% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $0.00 | -$10.00K |
| YoY Change | -100.0% | -50.0% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $1.540M | $1.460M | $4.690M |
| YoY Change | -66.88% | -68.87% | -5.44% |
| Cash From Investing Activities | $1.550M | $1.450M | $4.680M |
| YoY Change | -66.67% | -69.02% | -5.07% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -1.060M | -610.0K | -1.360M |
| YoY Change | -35.37% | -55.15% | -103.92% |
| NET CHANGE | |||
| Cash From Operating Activities | -5.600M | -6.710M | -8.230M |
| Cash From Investing Activities | 1.550M | 1.450M | 4.680M |
| Cash From Financing Activities | -1.060M | -610.0K | -1.360M |
| Net Change In Cash | -5.110M | -5.870M | -4.910M |
| YoY Change | 164.77% | 19.55% | -121.2% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$5.600M | -$6.710M | -$8.230M |
| Capital Expenditures | $0.00 | $0.00 | -$10.00K |
| Free Cash Flow | -$5.600M | -$6.710M | -$8.220M |
| YoY Change | 13.36% | -18.37% | -50.06% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018 | cris |
Available For Sale Securities Weighted Average Maturity
AvailableForSaleSecuritiesWeightedAverageMaturity
|
P1M6D | |
| cris |
Available For Sale Securities Weighted Average Maturity
AvailableForSaleSecuritiesWeightedAverageMaturity
|
P3M13D | ||
| CY2017Q1 | cris |
Cash Distribution Paidto Parent Company
CashDistributionPaidtoParentCompany
|
26600000 | USD |
| CY2017Q1 | cris |
Cash Distribution Paidto Parent Company
CashDistributionPaidtoParentCompany
|
26600000 | USD |
| CY2018 | cris |
Collaboration Agreement Exclusivity Payment
CollaborationAgreementExclusivityPayment
|
10000000 | USD |
| cris |
Collaboration Agreement Exclusivity Payment
CollaborationAgreementExclusivityPayment
|
2000000 | USD | |
| CY2016Q3 | cris |
Collaboration Agreement Numberof Programs Licensed
CollaborationAgreementNumberofProgramsLicensed
|
4 | program |
| cris |
Collaboration Agreement Numberof Programs Licensed
CollaborationAgreementNumberofProgramsLicensed
|
4 | program | |
| CY2019Q3 | cris |
Collaborative Arrangement Numberof Optional Additional Terms
CollaborativeArrangementNumberofOptionalAdditionalTerms
|
3 | term |
| CY2017Q3 | cris |
Collaborative Arrangement Option Fees Numberof Payments
CollaborativeArrangementOptionFeesNumberofPayments
|
2 | payment |
| cris |
Collaborative Arrangement Option Fees Total
CollaborativeArrangementOptionFeesTotal
|
7500000 | USD | |
| cris |
Collaborative Arrangement Optional Additional Term
CollaborativeArrangementOptionalAdditionalTerm
|
P1Y | ||
| cris |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
0 | USD | |
| cris |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-749000 | USD | |
| CY2010Q4 | cris |
Lessee Operating Lease Area Of Leased Property
LesseeOperatingLeaseAreaOfLeasedProperty
|
24529 | sqft |
| CY2010Q4 | cris |
Lessee Operating Lease Option To Extend Number Of Periods
LesseeOperatingLeaseOptionToExtendNumberOfPeriods
|
1 | period |
| CY2018Q3 | cris |
Monthly Retainerfor Advisory Services
MonthlyRetainerforAdvisoryServices
|
35000 | USD |
| CY2018Q3 | cris |
Non Cash Imputed Interest Expense
NonCashImputedInterestExpense
|
0 | USD |
| cris |
Non Cash Imputed Interest Expense
NonCashImputedInterestExpense
|
0 | USD | |
| CY2019Q3 | cris |
Non Cash Imputed Interest Expense
NonCashImputedInterestExpense
|
1303000 | USD |
| cris |
Non Cash Imputed Interest Expense
NonCashImputedInterestExpense
|
2721000 | USD | |
| cris |
Non Cash Imputed Interest Expense Net Of Imputed Interest
NonCashImputedInterestExpenseNetOfImputedInterest
|
0 | USD | |
| cris |
Non Cash Imputed Interest Expense Net Of Imputed Interest
NonCashImputedInterestExpenseNetOfImputedInterest
|
267000 | USD | |
| cris |
Non Cash Lease Expense
NonCashLeaseExpense
|
0 | USD | |
| cris |
Non Cash Lease Expense
NonCashLeaseExpense
|
673000 | USD | |
| CY2017Q4 | cris |
Operating Lease Cash Obligation Extended Term
OperatingLeaseCashObligationExtendedTerm
|
2000000 | USD |
| CY2017Q4 | cris |
Operating Lease Cash Obligation Initial Term
OperatingLeaseCashObligationInitialTerm
|
4400000 | USD |
| cris |
Operating Lease Interest Expense Income
OperatingLeaseInterestExpenseIncome
|
0 | USD | |
| cris |
Operating Lease Interest Expense Income
OperatingLeaseInterestExpenseIncome
|
50000 | USD | |
| cris |
Payments Of Future Royalty Liability
PaymentsOfFutureRoyaltyLiability
|
3593000 | USD | |
| cris |
Payments Of Future Royalty Liability Net Of Imputed Interest
PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest
|
0 | USD | |
| cris |
Payments Of Future Royalty Liability Net Of Imputed Interest
PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest
|
1139000 | USD | |
| cris |
Paymentsof Issuance Costs On Royalty Interest Purchase Agreement
PaymentsofIssuanceCostsOnRoyaltyInterestPurchaseAgreement
|
0 | USD | |
| cris |
Paymentsof Issuance Costs On Royalty Interest Purchase Agreement
PaymentsofIssuanceCostsOnRoyaltyInterestPurchaseAgreement
|
584000 | USD | |
| cris |
Proceeds From Royalty Purchase Agreement
ProceedsFromRoyaltyPurchaseAgreement
|
0 | USD | |
| CY2019Q1 | cris |
Royalty Purchase Agreement Liability
RoyaltyPurchaseAgreementLiability
|
65000000 | USD |
| dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
| cris |
Proceeds From Royalty Purchase Agreement
ProceedsFromRoyaltyPurchaseAgreement
|
65000000 | USD | |
| CY2018Q3 | cris |
Related Party Transaction Terms And Manner Of Settlement Maximum Days To Cure Material Breach
RelatedPartyTransactionTermsAndMannerOfSettlementMaximumDaysToCureMaterialBreach
|
5 | day |
| CY2018Q4 | cris |
Royalty Guarantees Commitments Amount Noncurrent
RoyaltyGuaranteesCommitmentsAmountNoncurrent
|
0 | USD |
| CY2019Q3 | cris |
Royalty Guarantees Commitments Amount Noncurrent
RoyaltyGuaranteesCommitmentsAmountNoncurrent
|
63544000 | USD |
| cris |
Royalty Purchase Agreement Accretion Expense
RoyaltyPurchaseAgreementAccretionExpense
|
2721000 | USD | |
| CY2019Q1 | cris |
Royalty Purchase Agreement Interest Rate
RoyaltyPurchaseAgreementInterestRate
|
0.079 | |
| cris |
Royalty Purchase Agreement Issuance Costs Capitalized
RoyaltyPurchaseAgreementIssuanceCostsCapitalized
|
584000 | USD | |
| CY2019Q1 | cris |
Royalty Purchase Agreement Liability
RoyaltyPurchaseAgreementLiability
|
65000000 | USD |
| CY2019Q3 | cris |
Royalty Purchase Agreement Liability Carrying Value
RoyaltyPurchaseAgreementLiabilityCarryingValue
|
63544000 | USD |
| CY2019Q1 | cris |
Royalty Purchase Agreement Transaction Fees And Closing Costs
RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts
|
600000 | USD |
| cris |
Share Based Compensation Plans
ShareBasedCompensationPlans
|
2 | plan | |
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2019 | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2019-09-30 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001108205 | ||
| CY2019Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
33202871 | shares |
| dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
| dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
CURIS INC | ||
| dei |
Entity Shell Company
EntityShellCompany
|
false | ||
| CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2909000 | USD |
| CY2019Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2478000 | USD |
| CY2018Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
2864000 | USD |
| CY2019Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
2897000 | USD |
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
131000 | USD | |
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
51000 | USD | |
| CY2018Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
3457000 | USD |
| CY2019Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1831000 | USD |
| CY2018Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
233000 | USD |
| CY2019Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
247000 | USD |
| CY2018Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
2774000 | USD |
| CY2019Q3 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
1319000 | USD |
| CY2018Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
0 | USD |
| CY2019Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
3000 | USD |
| CY2018Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
980012000 | USD |
| CY2019Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
982020000 | USD |
| CY2018Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1226000 | USD |
| CY2018Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1189000 | USD |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
651000 | USD |
| CY2019Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
631000 | USD |
| CY2019Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
684000 | USD |
| CY2019Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
684000 | USD |
| us-gaap |
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
1509000 | USD | |
| us-gaap |
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
2927000 | USD | |
| CY2018Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
895000 | USD |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3309000 | USD | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1966000 | USD | |
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
25000 | USD | |
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
8000 | USD | |
| CY2018Q4 | us-gaap |
Assets
Assets
|
37365000 | USD |
| CY2019Q3 | us-gaap |
Assets
Assets
|
42244000 | USD |
| CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
27961000 | USD |
| CY2019Q3 | us-gaap |
Assets Current
AssetsCurrent
|
32683000 | USD |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | USD |
| CY2019Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
3000 | USD |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
0 | USD |
| CY2019Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
0 | USD |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
634000 | USD |
| CY2019Q3 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
6649000 | USD |
| CY2018Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
634000 | USD |
| CY2019Q3 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
6652000 | USD |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
23636000 | USD |
| CY2019Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
21357000 | USD |
| CY2019Q3 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
28000000 | USD |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
38288000 | USD |
| CY2018Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
25561000 | USD |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
23636000 | USD |
| CY2019Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
21357000 | USD |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-12727000 | USD | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-2279000 | USD | |
| CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2019Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2018Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
67500000 | shares |
| CY2019Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
101250000 | shares |
| CY2018Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
67500000 | shares |
| CY2018Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
45000000 | shares |
| CY2019Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
101250000 | shares |
| CY2019Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
67500000 | shares |
| CY2018Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
33159253 | shares |
| CY2019Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
33202871 | shares |
| CY2018Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
33159253 | shares |
| CY2019Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
33202871 | shares |
| CY2018Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
332000 | USD |
| CY2019Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
332000 | USD |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-8000 | USD | |
| CY2018Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-7222000 | USD |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-26632000 | USD | |
| CY2019Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-6433000 | USD |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-23530000 | USD | |
| CY2018Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
9264000 | USD |
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
31858000 | USD | |
| CY2019Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
8179000 | USD |
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
23739000 | USD | |
| CY2019Q3 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
0 | USD |
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
139000 | USD | |
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
97000 | USD | |
| CY2018Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.22 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.80 | ||
| CY2019Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.19 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.71 | ||
| CY2019Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
3700000 | USD |
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y6M15D | ||
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | USD | |
| CY2018Q3 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | USD |
| us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | USD | |
| CY2019Q3 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | USD |
| us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-3495000 | USD | |
| CY2018Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4127000 | USD |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
11741000 | USD | |
| CY2019Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2887000 | USD |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8557000 | USD | |
| CY2018Q4 | us-gaap |
Goodwill
Goodwill
|
8982000 | USD |
| CY2019Q3 | us-gaap |
Goodwill
Goodwill
|
8982000 | USD |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1913000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-2006000 | USD | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-218000 | USD | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
33000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
138000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
798000 | USD | |
| CY2018Q3 | us-gaap |
Interest Expense
InterestExpense
|
972000 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
2990000 | USD | |
| CY2019Q3 | us-gaap |
Interest Expense
InterestExpense
|
0 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
791000 | USD | |
| CY2018Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
165000 | USD |
| CY2019Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
0 | USD |
| CY2018Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
166000 | USD |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
541000 | USD | |
| CY2019Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
170000 | USD |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
513000 | USD | |
| us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
800000 | USD | |
| CY2019Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
419000 | USD |
| CY2019Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
168000 | USD |
| CY2019Q3 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
251000 | USD |
| CY2019Q3 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
10000 | USD |
| CY2010Q4 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P5Y | |
| CY2017Q4 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P2Y | |
| CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
41861000 | USD |
| CY2019Q3 | us-gaap |
Liabilities
Liabilities
|
68262000 | USD |
| CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
37365000 | USD |
| CY2019Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
42244000 | USD |
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
13250000 | USD |
| CY2019Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4718000 | USD |
| CY2018Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
6884000 | USD |
| CY2019Q3 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
0 | USD |
| CY2018Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
28600000 | USD |
| CY2019Q3 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
0 | USD |
| CY2018Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
634000 | USD |
| CY2019Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
6652000 | USD |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-4322000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
24332000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
16720000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-6005000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-25125000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-20606000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-20600000 | USD | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10747000 | USD |
| CY2018Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8664000 | USD |
| CY2018Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7223000 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-26634000 | USD | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9884000 | USD |
| CY2019Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7213000 | USD |
| CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6436000 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-23500000 | USD | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-23533000 | USD | |
| CY2018Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-806000 | USD |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2449000 | USD | |
| CY2019Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1113000 | USD |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-6511000 | USD | |
| us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | segment | |
| CY2018Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6417000 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-24185000 | USD | |
| CY2019Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5323000 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17022000 | USD | |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
800000 | USD | |
| CY2019Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
409000 | USD |
| CY2019Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
409000 | USD |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
418000 | shares | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.88 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
3000 | USD | |
| CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-984840000 | USD |
| CY2019Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
373000 | USD |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
1170000 | USD |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
1002000 | USD |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
168000 | USD |
| CY2018Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
285000 | USD |
| CY2019Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
265000 | USD |
| CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
2000 | USD |
| CY2019Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
3000 | USD |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-4000 | USD |
| CY2018Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
5000 | USD |
| CY2018Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
1000 | USD |
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
2000 | USD | |
| CY2019Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
3000 | USD |
| CY2018Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
11000 | USD |
| CY2019Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
0 | USD |
| CY2018Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
0 | USD |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
0 | USD | |
| CY2019Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
20000 | USD |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-17000 | USD | |
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
26145000 | USD | |
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
10914000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
85000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
41000 | USD | |
| CY2018Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
827000 | USD |
| CY2019Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1624000 | USD |
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
|
112000 | USD | |
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
|
42000 | USD | |
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
42950000 | USD | |
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
4950000 | USD | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
267000 | USD |
| CY2019Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
203000 | USD |
| us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
4434000 | USD | |
| us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
1825000 | USD | |
| us-gaap |
Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
|
0 | USD | |
| us-gaap |
Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
|
37162000 | USD | |
| CY2018Q3 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
4983000 | USD |
| us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
19700000 | USD | |
| CY2019Q3 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
5147000 | USD |
| us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
14840000 | USD | |
| CY2018Q4 | us-gaap |
Restricted Investments
RestrictedInvestments
|
200000 | USD |
| CY2019Q3 | us-gaap |
Restricted Investments
RestrictedInvestments
|
200000 | USD |
| CY2018Q4 | us-gaap |
Restricted Investments Current
RestrictedInvestmentsCurrent
|
0 | USD |
| CY2019Q3 | us-gaap |
Restricted Investments Current
RestrictedInvestmentsCurrent
|
153000 | USD |
| CY2018Q4 | us-gaap |
Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
|
153000 | USD |
| CY2019Q3 | us-gaap |
Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
|
0 | USD |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.720 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1966000 | USD | |
| CY2019Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1008373000 | USD |
| CY2019Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1000000000 | USD |
| CY2018Q3 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
2847000 | USD |
| us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
7673000 | USD | |
| CY2019Q3 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
2856000 | USD |
| us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
6717000 | USD | |
| CY2018Q3 | us-gaap |
Royalty Expense
RoyaltyExpense
|
154000 | USD |
| us-gaap |
Royalty Expense
RoyaltyExpense
|
417000 | USD | |
| CY2019Q3 | us-gaap |
Royalty Expense
RoyaltyExpense
|
145000 | USD |
| us-gaap |
Royalty Expense
RoyaltyExpense
|
342000 | USD | |
| CY2018 | us-gaap |
Severance Costs1
SeveranceCosts1
|
300000 | USD |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3309000 | USD | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.787 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.660 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.758 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.028 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.026 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.025 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.023 | ||
| CY2019Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1435808 | shares |
| CY2019Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
8.84 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
0 | USD | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
0 | USD | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
1577558 | shares | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
3875865 | shares | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.46 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.83 | ||
| CY2019Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
3797000 | USD |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3714394 | shares |
| CY2019Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6012701 | shares |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
7.68 | |
| CY2019Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
3.48 | |
| CY2019Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
3.75 | |
| CY2019Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
3200000 | USD |
| CY2019Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
5284182 | shares |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.00 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
7.95 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.26 | ||
| CY2019Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
122000 | USD |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y6M6D | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y6M10D | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P8Y5M4D | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares | |
| CY2018Q3 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
895000 | USD |
| CY2018Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
112000 | USD |
| CY2019Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-26018000 | USD |
| CY2018Q2 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.2 | |
| CY2018Q1 | us-gaap |
Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
|
1500000 | USD |
| CY2019Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
42000 | USD |
| CY2018Q3 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
|
0 | USD |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
0 | USD |
| CY2002Q4 | us-gaap |
Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
|
3000000 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
23993000 | USD |
| CY2018Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14468000 | USD |
| CY2018Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
7110000 | USD |
| CY2018Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
782000 | USD |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-4496000 | USD |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-13729000 | USD |
| CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-20269000 | USD |
| CY2018Q1 | us-gaap |
Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
|
0 | USD |
| us-gaap |
Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
|
244569.2 | shares | |
| CY2018Q1 | us-gaap |
Treasury Stock Shares Retired
TreasuryStockSharesRetired
|
244569.2 | shares |
| us-gaap |
Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
|
1500000 | USD | |
| CY2018Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
33161592 | shares |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
33117290 | shares | |
| CY2019Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
33202871 | shares |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
33170844 | shares | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Nature of Business</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Curis, Inc. is a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. As used throughout these Condensed Consolidated Financial Statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company conducts its research and development programs both internally and through strategic collaborations. The Company’s clinical stage drug candidates are fimepinostat, CA-4948, and CA-170:</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fimepinostat is currently being explored in clinical studies in patients with MYC-altered diffuse large B-cell lymphoma (“DLBCL”) and solid tumors and has been granted Orphan Drug Designation and Fast Track Designation for the treatment of DLBCL by the U.S. Food and Drug Administration, (“FDA”) in April 2015 and May 2018, respectively. The Company has begun enrollment in a Phase 1 combination study with venetoclax in DLBCL patients, including patients with translocations in both MYC and the BCL2 gene, also referred to as double-hit lymphoma, or high grade B-cell lymphoma (“HGBL”). The Company expects to report initial clinical data from this combination study in the fourth quarter of 2019. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CA-4948 is being tested in a dose escalating clinical trial in patients with non-Hodgkin lymphomas, including those with myeloid differentiation primary response 88, or MYD88, alterations. The Company is currently planning to initiate a separate Phase 1 trial for acute myeloid leukemia (“AML”) and myelodysplastic syndromes (“MDS”) patients. The Company expects to report further clinical data from the study in the fourth quarter of 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CA-170 is currently undergoing testing in a clinical study in patients with mesothelioma. The Company will announce initial data in conjunction with the Society for Immunotherapy of Cancer conference in November 2019. Based on this data, no further patients will be enrolled in the study. The Company is currently evaluating future studies for CA-170.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s pipeline also includes CA-327, which is a pre-Investigational New Drug (“IND”) stage oncology drug candidate. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is party to a collaboration with Genentech Inc. (“Genentech”), a member of the Roche Group, under which F. Hoffmann-La Roche Ltd (“Roche”) and Genentech are commercializing Erivedge</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM </sup></font><font style="font-family:inherit;font-size:10pt;">(vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway inhibitor. Erivedge is approved for the treatment of advanced basal cell carcinoma (“BCC”).</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, and as amended in September 2016, the Company entered into a collaboration, option and license agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited (“Aurigene”).</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaboration with Aurigene comprises multiple programs, and the Company has the option to exclusively license each program, including data, intellectual property and compounds associated therewith, once a development candidate is nominated within such program. In October 2015, the Company exercised options to license </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> programs under this collaboration. The first licensed program is in the immuno-oncology field and the Company has named CA-170, an orally available small molecule antagonist of two immune checkpoints, V-domain Ig suppressor of T-cell activation (“VISTA”) and programmed death ligand-1 (“PDL1”), as the development candidate from this program. The second licensed program is in the precision oncology field and the Company has named CA-4948, an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (“IRAK4”) as the development candidate. In October 2016, the Company exercised its option to license a third program in the collaboration, and designated CA-327, a distinct orally available small molecule antagonist of two immune checkpoints PDL1 and T-cell immunoglobulin and mucin domain containing protein-3 (“TIM3”) as the development candidate from this program. In March 2018, the Company exercised its option to license a fourth program, which is an immuno-oncology program. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the healthcare industry and would be regulated in the United States by the FDA and in overseas markets by similar regulatory authorities.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to advance and expand its research and development programs, the Company’s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties’ collaboration agreement, the Company’s reliance on Roche and Genentech to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC, the Company’s ability to obtain adequate financing to fund its operations, the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC (“Curis Royalty”), to satisfy the terms of the royalty interest purchase agreement (the “Oberland Purchase Agreement”) with entities managed by Oberland Capital Management, LLC (“Purchasers”), the Company’s ability to obtain and maintain necessary intellectual property protection, development by the Company’s competitors of new or better technological innovations, the Company's dependence on key personnel, the Company’s ability to comply with regulatory requirements, the Company's ability to obtain and maintain applicable regulatory approvals and commercialize any approved product candidates, and the Company’s ability to execute on its overall business strategies.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it may receive and make under its current and potential future collaborations. The results of the Company’s operations have varied and will likely continue to vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; Aurigene’s ability to successfully discover and develop preclinical programs under the Company’s collaboration with Aurigene, as well as the Company’s decision to exclusively license and further develop programs under this collaboration; Roche and Genentech’s ability to successfully commercialize Erivedge; and positive results in Roche and Genentech’s ongoing clinical trials.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred net losses and negative cash flows from operations since its inception. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.0</font><font style="font-family:inherit;font-size:10pt;"> billion, and for the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred a net loss of </font><font style="font-family:inherit;font-size:10pt;">$23.5</font><font style="font-family:inherit;font-size:10pt;"> million and used </font><font style="font-family:inherit;font-size:10pt;">$20.6</font><font style="font-family:inherit;font-size:10pt;"> million of cash in operations. The Company expects to continue to generate net losses in the foreseeable future. The Company anticipates that its </font><font style="font-family:inherit;font-size:10pt;">$28.0</font><font style="font-family:inherit;font-size:10pt;"> million of existing cash, cash equivalents and investments at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> should enable the Company to maintain its planned operations into the second half of 2020. Based on available cash resources, the Company does not have sufficient cash on hand to support current operations within the next 12 months from the date of filing this Quarterly Report on Form 10-Q. The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control and it may be unable to raise financing when needed, or on terms favorable to the Company. If sufficient funds are not available, the Company may have to delay, reduce the scope of, or eliminate some of its research and development programs, including related clinical trials and operating expenses, potentially delaying the time to market for or preventing the marketing of any of its product candidates, which could adversely affect the Company’s business prospects and the Company’s ability to continue its operations, and would have a negative impact on the Company’s financial condition and ability to pursue its business strategies. See Note 2, “Basis of Presentation,” for additional information about the Company’s ability to continue as a going concern.</font></div></div> | ||
| us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Reclassifications and Revision</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior period amounts have been reclassified to conform with the current period presentation.</font></div></div> | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the Company’s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements; the estimated repayment term of the Company’s debt and related short- and long-term classification; the fair value of the Company’s debt; the collectability of receivables; the carrying value of property and equipment and intangible assets; and the assumptions used in the Company’s valuation of stock-based compensation and the value of certain investments and liabilities. Actual results may differ from such estimates.</font></div></div> |
